uniQure NV

uniQure NV a gene therapy company engages in the development of treatments for patients suffering from genetic and other devastating diseases Its lead program is Etranacogene dezaparvovec AMT061 which is in Phase III HOPEB pivotal trial for the treatment of hemophilia B The company also engages in developing AMT130 a gene therapy that is in Phase III clinical study for the treatment of Huntingtons disease AMT060 which is in Phase III clinical trial for the treatment of hemophilia B AMT210 a product candidate for the treatment of Parkinsons disease AMT260 for temporal lobe epilepsy AMT240 a preclinical product candidate for the treatment of autosomal dominant Alzheimers disease and AMT161 for the treatment of amyotrophic lateral sclerosis uniQure NV was founded in 1998 and is headquartered in Amsterdam the Netherlands